qualified, including evidence of experience similar to this project.

5. Budget (not scored)

The extent to which itemized budget for conducting the project, along with justification, is reasonable and consistent with stated objectives and planned program activities.

6. Human Subjects (not scored)

The applicant must state if there is a need of human subjects review and describe a plan for the review of their proposed project by an accredited review board. The CDC Institutional Review Board (IRB) will review and approve the protocol initially and on at least an annual basis until the research project is completed.

I. Other Requirements

Technical Reporting Requirements

Provide CDC with original plus two copies of

- 1. Semi-annual progress reports. The progress report will include a data requirement that demonstrates measures of effectiveness.
- 2. Financial status report, no more than 90 days after the end of the budget period.
- 3. Final financial and performance reports, no more than 90 days after the end of the project period.

Awardee is required to obtain an annual audit of these CDC funds (program specific audit) by a U.S. based audit firm with international branches and current license/authority incountry, and in accordance with International Accounting Standards or equivalent.

A fiscal Recipient Capability
Assessment may be required, pre-award
or post-award, with the potential
awardee in order to review their
business management and fiscal
capabilities regarding the handling of
U.S. Federal funds. Send all reports to
the Grants Management Specialist
identified in the "Where to Obtain
Additional Information" section of this
announcement in the application kit.

The following additional requirements are applicable to this program.

AR-1 Human Subjects

AR-7 Executive Order 12372 Review

AR–8 Public Health System Reporting Requirements

AR–10 Smoke-Free Workplace Requirements

AR-11 Healthy People 2010

AR-12 Lobbying Restrictions

AR-14 Accounting

J. Where to Obtain Additional Information

This and other CDC announcements, and the necessary application and associated forms can be found on the CDC home page Internet address—http://www.cdc.gov Click on "Funding" then "Grants and Cooperative Agreements."

To obtain business management technical assistance, contact: Vincent Falzone, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention, 2920 Brandywine Road, Room 3000, Atlanta, GA 30341–4146, Telephone number: 770–488–2763, Email address: vfalzone@cdc.gov.

For program technical assistance, contact: Barbara Lopes Cardozo, International Emergency Refugee Health Branch, Division of Emergency and Environmental Health Services, National Center for Environmental Health, Centers for Disease Control and Prevention, 4770 Buford Highway, NE (F–48), Atlanta, GA 30341, Telephone number: (770) 488–4138, Email address: BLopesCardozo@cdc.gov.

Dated: June 29, 2002.

Sandra R. Manning,

CGFM, Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 02–16938 Filed 7–5–02; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Sleep Disorders Research

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Sleep Disorders Research.

Times and Dates: 2:00 p.m.–2:30 p.m., July 23, 2002 (Open); 2:40 p.m.–4:00 p.m., July 23, 2002 (Closed).

Place: Teleconference number (513) 841–4560.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to a FY02 Congressional appropriation.

Contact Person for More Information: Kathleen Goedel, National Institute for Occupational Safety and Health, CDC, 4676 Columbia Parkway Cincinnati, OH., telephone (513) 841–4560.

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: July 2, 2002.

Joe Salter,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 02–17101 Filed 7–5–02; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: New Investigator Awards for Unintentional, Violence, and Acute Case, Disability, and Rehabilitation Related Prevention Research, Program Announcement #02121

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): New Investigator Awards for Unintentional, Violence, and Acute Case, Disability, and Rehabilitation Related Prevention Research, Program Announcement #02121.

Times and Dates: 6:00 p.m.-6:30 p.m., July 28, 2002 (Open); 6:30 p.m.-8:00 p.m., July 28, 2002 (Closed); 9:00 a.m.-5:00 p.m., July 29, 2002 (Closed).

Place: The Westin Hotel (Atlanta Airport) 4736 Best Road, Atlanta, GA 30337 Phone: (404) 762–7676.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to PA# 02121.

Contact Person for More Information: Dr. Lynda Doll, Associate Director for Science,